<4-(3-pyridylcarbonylamino)-2-phenylbenzoyl>methionine methyl ester | 191101-16-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: <4-(3-pyridylcarbonylamino)-2-phenylbenzoyl>methionine methyl ester
• 英文别名: [4-(3-Pyridylcarbonylamino)-2-phenylbenzoyl]methionine methyl ester；methyl (2S)-4-methylsulfanyl-2-[[2-phenyl-4-(pyridine-3-carbonylamino)benzoyl]amino]butanoate
• CAS: 191101-16-3
• 化学式: C₂₅H₂₅N₃O₄S
• 分子量: 463.557
• InChiKey: FIVQMEKKAKHRHR-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  <4-(3-pyridylcarbonylamino)-2-phenylbenzoyl>methionine methyl ester 在 lithium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 (S)-4-Methylsulfanyl-2-({5-[(pyridine-3-carbonyl)-amino]-biphenyl-2-carbonyl}-amino)-butyric acid; hydrochloride
  参考文献：
  名称：

  Potent and Selective Non-Cysteine-Containing Inhibitors of Protein Farnesyltransferase

  摘要：

  Potent and selective non-thiol-containing inhibitors of protein farnesyltransferase are described. FTI-276 (1) was transformed into pyridyl ether analogue 19. The potency of pyridyl ether 19 was improved by modification of the biphenyl core to that of an o-tolyl substituted biphenyl core to give 29. In addition to 0.4 nM in vitro potency, 29 displayed 350 nM potency in whole cells as the parent carboxylic acid. The o-tolyl biphenyl core dramatically and unexpectedly enhanced the potency of other compounds as exemplified by 46, 47, 48, and 49.

  DOI：

  10.1021/jm980298s
• 作为产物：
  描述：

  烟酸 在 草酰氯 、 碳酸氢钠 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 <4-(3-pyridylcarbonylamino)-2-phenylbenzoyl>methionine methyl ester
  参考文献：
  名称：

  Potent and Selective Non-Cysteine-Containing Inhibitors of Protein Farnesyltransferase

  摘要：

  Potent and selective non-thiol-containing inhibitors of protein farnesyltransferase are described. FTI-276 (1) was transformed into pyridyl ether analogue 19. The potency of pyridyl ether 19 was improved by modification of the biphenyl core to that of an o-tolyl substituted biphenyl core to give 29. In addition to 0.4 nM in vitro potency, 29 displayed 350 nM potency in whole cells as the parent carboxylic acid. The o-tolyl biphenyl core dramatically and unexpectedly enhanced the potency of other compounds as exemplified by 46, 47, 48, and 49.

  DOI：

  10.1021/jm980298s

文献信息

• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
• INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES
  申请人：UNIVERSITY OF PITTSBURGH

  公开号：EP0873123B1

  公开（公告）日：2003-04-09
• EP0873123A4
  申请人：——

  公开号：EP0873123A4

  公开（公告）日：1999-02-03
• US6693123B2
  申请人：——

  公开号：US6693123B2

  公开（公告）日：2004-02-17
• [EN] INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES<br/>[FR] INHIBITEURS DE PROTEINE-ISOPRENYLE-TRANSFERASES
  申请人：UNIVERSITY OF PITTSBURGH

  公开号：WO1997017070A1

  公开（公告）日：1997-05-15

  (EN) Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R1 is selected from: (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halogen, (g) haloalkyl, (h) aryl-L2 - and (i) heterocyclic - L3; R2 is selected from the group consisting of: (a) formula (II), (b) -C(O)NH-CH(R14)-C(O)OR15, (c) formula (III), (d) -C(O)NH-CH(R14)-C(O)NHSO2R16, (e) -C(O)NH-CH(R14)-tetrazolyl, (f) -C(O)NH-heterocyclic, and (g) -C(O)NH-CH(R14)-C(O)NR17R18; R3 is pyridyl, substituted pyridyl, imidazolyl, or substituted imidazolyl; R4 is selected from hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, and (heterocyclic)alkyl; and L1 is absent or is selected from (a) -L4-N(R4)-L5-, (b) -L4-O-L5-, (c) -L4-S(O)n-L5-, (d) -L4-L6-C(W)-N(R5)-L5-, (e) -L4-L6-S(O)m-N(R7)-L5-, (f) -L4-N(R7)-C(W)-L7-L5-, (g) -L4-N(R7)-S(O)p-L7-L5-, (h) C2-C4-alkylene optionally substituted with 1 or 2 hydroxy groups, (i) C2-to-C4-alkenylene, and (j) C2-to-C4-alkynylene, are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.(FR) L'invention concerne des composés représentés par la formule (I) ou un sel pharmaceutiquement acceptable de ces composés. Dans ladite formule R1 est choisi parmi: (a) hydrogène, (b) alkyle inférieur, (c) alcenyl, (d) alcoxy, (e) thioalcoxy, (f) halogène, (g) haloalkyle, (h) aryle-L2- et (i) hétérocyclique-L3-; R2 est choisi dans le groupe qui comprend: (a) la formule (II), (b) -C(O)NH-CH(R14)-C(O)OR15, (c) la formule (III), (d) -C(O)NH-CH(R14)-C(O)NHSO2R16, (e) -C(O)NH-CH(R14)-tétrayolyle, (f) -C(O)NH-hétérocyclique, et (g) -C(O)NH-CH(R14)-C(O)NR17R18; R3 est pyridile, pyridile substitué, imidazolyle ou imidazolyle substitué; R4 est choisi hydrogène, alkyle inférieur, haloalkyle, halogène, aryle, arylalkyle, hétérocyclique et alkyle(hétérocyclique); et L1 est absent ou choisi parmi (a) -L4-N(R4)-L5-, (b) -L4-O-L5-, (c) -L4-S(O)n-L5-, (d)-L4-L6-C(W)-N(R5)-L5-, (e) -L4-L6-S(O)m-N(R7)-L5-, (f) -L4-N(R7)-C(W)-L7-L5-, (g) -L4-N(R7)-S(O)p-L7-L5-, (h) alkylène C2-C4 éventuellement substitué par un ou deux groupes hydroxy, (i) alcénylène C2-C4, et (j) alcynylène C2-C4. Ces produits sont des inhibiteurs de protéine-isoprényle-transférase. On décrit par ailleurs des compositions et un procédé qui inhibent la protéine-isoprényle-transférase.